News

January 8, 2021 - Peptone, a UK-based startup that is helping pharmaceutical companies unravel the secrets of proteins, has raised a $2.5m seed round from backers hoping the company can unlock one of the most pernicious problems of medicine.

January, 7, 2021 - Aspen RxHealth, whose first of its kind clinical pharmacy model developed by pharmacists for pharmacists delivers value for health plans and risk-bearing providers, today announced the closure of a $23 million Series B funding round led by  Bessemer Venture Partners. Multiple strategic partners participated in this round, including Takeda Digital Ventures, dRx Capital (Novartis' Digital Venture Fund), and McKesson Ventures. Previous investors Humana and Flare Capital Partners also participated.

December 22, 2020 - SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that it added $81M to its current funding round with investments from a number of additional investors, for a total Series A raise of $214M. The funds raised in this round will facilitate improving, expanding and commercializing SomaLogic’s world-leading proteomic products in both the clinical and life science markets.

October 22, 2020 - Burlingame, Calif.-based Cala Health’s Cala Trio is FDA cleared to relieve hand tremors from essential tremor (ET), but the company is now nearing the initiation of clinical trials to evaluate the therapy in treating action hand tremors in adult patients with Parkinson’s disease.

September 28, 2020 - Koneksa, the leader in developing and implementing patient-centric digital biomarkers for drug development, announced today the completion of a $16M Series B financing round. The company plans to use the investment to expand the development of its digital platform for integrating wearables, sensors, and other patient-facing technologies into clinical research.

August 26, 2020 - Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced an oversubscribed $270 million Series C financing, bringing the company's total financing to over $500 million since the company’s launch. The proceeds will be used to accelerate the PREEMPT CRC™ clinical trial for Freenome’s blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the company’s proprietary multiomics platform. PREEMPT CRC is an FDA registrational study launched in May 2020 to support approval by the U.S. Food and Drug Administration (FDA) for the first front-line blood test to help the 45 million people who are currently not up-to-date on colorectal cancer screening guidelines in the U.S.

August 20, 2020 - Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round. Existing investors Lux Capital, Redmile Group, and PPD, Inc. (Nasdaq: PPD) led the round, and are joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn Capital. Notable new investors include LifeSci Ventures and Mubadala Ventures.